Current anti-inflammatory drugs in MS are being used systemically at high doses. Thus, they are associated with severe side effects, including increased risk of general and respiratory infections and hyperglycemia. Therefore, it is crucial to find safer and more effective drug delivery systems in these settings. Nanoparticles are promising carriers for targeted delivery of therapeutic agents. Investigating the approaches based on nanoparticles is one of the main focuses of our lab.